Table 8.
Integrative Herbal Medicine: Chemotherapy-Related Hand-Foot Syndrome (NCI-CTCAE).a
| Chemotherapy Regimen | Participants: Characteristics (No.) | Effect Size RR [95% CI] I2 | Study ID |
|---|---|---|---|
| Grade III | |||
| XELOX (without surgery) | Advanced or recurrent stage IV CRC (97) | Both groups=0 events | 22 |
| Stage IV CRC (53) | 0.32 [0.01, 7.55] | 18 | |
| Advanced colon cancer (96) | 0.20 [0.01, 4.06] | 32 | |
| Pooled result | 2 (149) | 0.25 [0.03, 2.22] 0% | 18, 32 |
| All grades | |||
| XELOX (without surgery) | Advanced CRC (62) | 0.70 [0.35, 1.43] | 16 |
| Advanced or recurrent stage IV CRC (97) | 0.98 [0.58, 1.65] | 22 | |
| Stage IV CRC (53) | 0.41 [0.23, 0.73]b | 18 | |
| Advanced colon cancer (96) | 1.50 [1.05, 2.15]b | 32 | |
| Pooled result (XELOX) | 4 (308) | 0.83 [0.46, 1.50] 80.4% | 16, 18, 22, 32 |
| FOLFOX4/FOLFOX6 | Advanced or recurrent CRC, placebo in control group (89) | 1.61 [0.69, 3.77] | 23 |
| Pooled result | 5 (397) | 0.93 [0.55, 1.55] 75.7% | All above |
Abbreviations: NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; CI, confidence interval; RR, relative risk; CRC, colorectal cancer.
a
All studies used oral herbal medicines combined with chemotherapy versus the same chemotherapy.
b
Statistically significant.